to block the excess endothelin by various means(passive) are designedEndothelin receptor antagonists
book inhibitorscomposedof receptor antagonists
both groupsresultof receptor antagonists
Pharmacological agentsdesignedas antagonists for these receptors
It is knowncausesNMDA receptors to downregulate
to block vasoconstricting peptides , which are believed to play an important role in essential hypertension(passive) are designedEndothelin receptor antagonists
Modern neuroscience ... specifically thoseinfluenceserotinergic receptors
physiological response at a specific receptorto causephysiological response at a specific receptor
The disease(passive) is caused byThe disease
to a progressive decline in receptor activitycan leadto a progressive decline in receptor activity
to anxietycan leadto anxiety
to increased cortical glutamate releaseleadto increased cortical glutamate release
The drug(passive) could have been designedThe drug
to tolerance , whereby the liver will more quickly eliminate NMDA receptor antagonists from the bloodstreamcan leadto tolerance , whereby the liver will more quickly eliminate NMDA receptor antagonists from the bloodstream
a certain type of [ [ brain damagecan causea certain type of [ [ brain damage
in addition to psychosis - like results cortical injurycausein addition to psychosis - like results cortical injury
a certain type of [ [ brain damage ] ] referred to as [ [ Olney 's Lesionscan causea certain type of [ [ brain damage ] ] referred to as [ [ Olney 's Lesions
of NR1composedof NR1
a certain type of neurotoxicity or brain damage referred to as Olney 's Lesions in rodentscan causea certain type of neurotoxicity or brain damage referred to as Olney 's Lesions in rodents
a certain type of brain damage referred to as Olney 's Lesions ( in rodentscan causea certain type of brain damage referred to as Olney 's Lesions ( in rodents
rigidity and eventually deaththus causingrigidity and eventually death
sluggishness and disorientationcausesluggishness and disorientation
to a compound currently in Phase II human trialsleadingto a compound currently in Phase II human trials
any damagecauseany damage
synthesis and release of these neurotransmitters which promotescausesynthesis and release of these neurotransmitters which promotes
synthesis and release of these neurotransmitters which promotes wakingcausesynthesis and release of these neurotransmitters which promotes waking
to inhibit FSH receptor pathway or the LH receptor pathwaydesignedto inhibit FSH receptor pathway or the LH receptor pathway
the opposite effectscausedthe opposite effects
in significant improvement in blood pressure and serum potassium level among patients with primary aldosteronismresultin significant improvement in blood pressure and serum potassium level among patients with primary aldosteronism
to pharmacological toleranceleadsto pharmacological tolerance
to constipationmay leadto constipation
a similar decrease in heart ratecauseda similar decrease in heart rate
in improved plasticityresultin improved plasticity
to analgesialeadingto analgesia
in more substantial painresultedin more substantial pain
in marked falls in blood pressurecan resultin marked falls in blood pressure